Cancer Cell Laboratory, Department of Biological Sciences, University of Lethbridge, Lethbridge, AB T1K 3M4, Canada.
Int J Mol Sci. 2017 Nov 6;18(11):2344. doi: 10.3390/ijms18112344.
One of the most common characteristics of cancer cells is genomic instability. Recent research has revealed that G2/M-phase checkpoint adaptation-entering mitosis with damaged DNA-contributes to genomic changes in experimental models. When cancer cells are treated with pharmacological concentrations of genotoxic agents, they undergo checkpoint adaptation; however, a small number of cells are able to survive and accumulate micronuclei. These micronuclei harbour damaged DNA, and are able to replicate and reincorporate their DNA into the main nucleus. Micronuclei are susceptible to chromothripsis, which is a phenomenon characterised by extensively rearranged chromosomes that reassemble from pulverized chromosomes in one cellular event. These processes contribute to genomic instability in cancer cells that survive a genotoxic anti-cancer treatment. This review provides insight into checkpoint adaptation and its connection to micronuclei and possibly chromothripsis. Knowledge about these mechanisms is needed to improve the poor cancer treatment outcomes that result from genomic instability.
癌细胞的一个最常见特征是基因组不稳定。最近的研究表明,G2/M 期检查点适应——带着受损 DNA 进入有丝分裂——有助于实验模型中的基因组变化。当癌细胞用具有遗传毒性的药物浓度处理时,它们会经历检查点适应;然而,少数细胞能够存活下来并积累微核。这些微核含有受损的 DNA,能够复制并将其 DNA 重新整合到主核中。微核容易发生染色体重排,这是一种广泛重排染色体的现象,它们在一个细胞事件中从粉碎的染色体中重新组装。这些过程导致在遗传毒性抗癌治疗中存活下来的癌细胞基因组不稳定。这篇综述提供了对检查点适应及其与微核和可能的染色体重排的联系的深入了解。了解这些机制对于改善由于基因组不稳定导致的癌症治疗效果不佳的情况是必要的。